anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Chronic kidney disease-mineral and bone metabolism disorder (CKD-MBD) is a common chronic kidney disease (CKD)-associated complication that increases the risk of metabolic bone diseases, fractures, osteoblastic trans-differentiation of vascular smooth muscle cells, and cardiovascular events. SD rats were randomised into five groups with six rats per group: sham, CKD, CKD + advanced glycosylation end products (AGEs), CKD + Quercetin, and CKD + AGEs + Quercetin. The protective effects of AGEs and quercetin on SD rats were assessed by renal function, renal pathology, bone metabolism, osteoblastic trans-differentiation of vascular smooth muscle cells, and the receptor for AGE (RAGE) expression. Compared with the control group, rats in the CKD and CKD + AGEs groups had significantly lower body weight, higher serum AGEs levels, impaired renal function, increased levels of oxidative stress in the kidney and bone marrow tissues, lower femoral bone mineral density (BMD), callus mineralised volume fraction (mineralised bone volume/total volume), abnormal serum bone metabolism levels, and increased renal tissue, bone tissue, and abdominal aorta RAGE expression levels, and the RAGE downstream NF-κB signalling pathway was upregulated. Quercetin significantly improved renal dysfunction, attenuated serum AGE levels, reduced oxidative stress levels in the kidney and bone marrow tissues, and downregulated RAGE expression in the kidney, bone, and abdominal aorta and the RAGE downstream NF-κB signalling pathway in rats with CKD. AGEs are involved in the pathogenesis of CKD-MBD by promoting osteoblastic trans-differentiation of vascular smooth muscle cells and abnormal bone metabolism. Quercetin plays a role in the prevention and treatment of CKD-MBD by reducing the production of AGEs.
PROBLEM TO BE SOLVED: To obtain a skin cosmetic which contains an extract from a specific plant in Lagminosae as an active ingredient and has excellent skin-whitening effect with no problem on safety on application. SOLUTION: An extract from Sesbania grandiflora or Agasti, a herbaceous shrub in Lagminosae is used as an active ingredient for this skin cosmetic. In the extraction of Sesbania grandiflora, a water-soluble organic solvent or water-containing water-soluble organic solvent is preferably used. The content of the Sesbania grandiflora extract is preferably 0.01-10wt.%, particularly 0.01-5wt.% based on the whole skin cosmetic. This skin cosmetic can improve skin dry feeling, gloss defect, fine wrinkles and roughening and can sufficiently with stand long-term application. This skin cosmetic is in the forms of, for example, skin lotion, milk emulsion, cream, pack, foundation cosmetic, lipstick, bath medicine and the like.
The invention relates to novel severe gastric acid environment-resistant polypeptide-polysaccharide nano-particles and a preparation method thereof. The nano-particles can be applied to medicine and food industry and serve as oral delivery carriers of functional factors of medicines and food. The chitosan-casein phosphopeptide nano-particles are cross-linked by adopting a natural cross-linking agent genipin, the cross-linking reaction conditions and centrifugal separation and purification conditions are optimized, the structural stability of the cross-linked nano-particles in the gastric acid environment is characterized, and novel high polymer nano-particles which can resist a severe gastric acid environment are successfully prepared. The process method has the advantages that the reaction conditions are mild, any organic reagent is not used, and the nano-particles are low in cost and environment-friendly. More importantly, huge toxic and side effects brought by application of chemical synthesis cross-linking agents are avoided when the chitosan nano-particles are cross-linked by adopting the natural genipin. Therefore, the nano-particles have wide application prospects.
Subjects of Group 1 take Fimasartan and Atorvastatin Individual Tablets at 1st day as period I. And then, after wash out for 7 days, as period II, subjects of Group 1 take a Fimasartan/Atorvastatin Combination Tablet at 8th day.
The ambient temperature of the operating room was set at 23±2 ℃ and the relative humidity was 50% to 60%. Intraoperative infusion fluids, blood products and rinsing fluid were warmed. Patients were given quilts to cover after entering the operating room, and the quilts covered from the neck to both the feet.
OBJECTIVE: The aim was to optimize diagnostics for carotid artery calcifications (CACs) on panoramic radiographs (PRs) to identify cardiovascular disease (CVD) by investigating how 4 defined CAC shapes are associated with ultrasound (US) findings indicating CVD.
STUDY DESIGN: The study included 414 participants (802 neck sides) from the Malmö Offspring Dental Study, examined with PRs. The PRs were assessed for CAC shapes stratified into 4 categories: single, scattered, vessel-width defining, and vessel-outlining. The carotid arteries were examined with US for signs of CVD: the presence of plaques, largest individual area of a plaque, number of plaques, and percentage reduction of the lumen. Associations between the different CAC categories and US characteristics were analyzed.
RESULTS: All categories of CAC were significantly associated with a higher degree of US findings indicating CVD compared with no CAC (P < .001). The most significant differences were found for vessel-outlining CAC, with the mean of the largest individual plaque area of 17.9 vs 2.3 mm2, mean number of plaques 1.6 vs 0.2, and mean percentage reduction of the lumen 24.1% vs 3.5% (all P < .001).
CONCLUSIONS: Independent of shape, CACs detected on PRs were associated with a higher degree of US findings of CVD. This was most pronounced for vessel-outlining CAC. With refined differential diagnostics of CACs in PRs, dentists may contribute to improved identification of patients in need of cardiovascular prevention.
INTRODUCTION: Chronic obstructive pulmonary disease (COPD) is a dynamic disease with a high socioeconomic burden. Using data collected prospectively from the general population, we examined factors related to the transition of at-risk individuals to COPD.
METHODS: We used the Korean Genome Epidemiology Study (KoGES) database, defining pre-COPD based on respiratory symptoms and radiological abnormalities suggestive of COPD; the preserved ratio impaired spirometry (PRISm) was defined as a forced expiratory volume in 1s (FEV1)/forced vital capacity ratio≥70% and FEV1<80%, as predicted by spirometry. We determined group differences in the rate of lung function decline, risk of future airflow obstruction (AFO).
RESULTS: The study included 4762 individuals, and longitudinal analysis revealed distinct trends in pulmonary function indicators. Compared to the normal group, the pre-COPD group showed a more rapid decline in lung function, while the PRISm group showed a slower decline. In the pre-COPD and PRISm groups, 4.4% and 3.5%, and 13.6% and 10.8%, respectively, of patients had progressed to COPD at the first and second visits. Pre-COPD and PRISm contributed to an earlier time to first AFO, but consideration of comorbid cardiovascular disease weakened this relationship in the PRISm group. Multivariate logistic regression showed that pre-COPD and PRISm are significant risk factors for future development of COPD (OR 1.80, p<0.001; OR 4.26, p<0.001, respectively).
CONCLUSION: Pre-COPD and PRISm patients showed different trends in lung function changes over time and both were significant risk factors for future development of COPD.
PROBLEM TO BE SOLVED: To obtain a dispersion of an agent containing the agent homogeneously dispersed in a solvent and having slow releasing property by thickening the viscosity of a dispersing liquid by adding a specific polymer and alkali salt and subsequently adding an inorganic porous fine particles carrying the agent to the dispersing liquid to disperse them. SOLUTION: This dispersion of an agent is obtained by compounding an inorganic porous fine particles carrying an agent, a dispersing liquid, an acrylic polymer and an alkali salt. The dispersing liquid is at least one selected from between water and an alcohol. A 1-3C alcohol is suitable to the alcohol. A repellent is preferable as the agent. An inorganic porous fine particle obtained by interface reaction is suitable to the inorganic porous fine particle. The agent is preferably carried on the inorganic porous fine particles at 1-500wt.%. The content of the inorganic porous fine particles in the dispersing liquid of the agent is 0.01-60wt.%. The content of the acrylic polymer is about 0.0001-6wt.%. The alkali compound is used for neutralizing the acrylic polymer, and an example of the alkali compound is poly(oxyethylene)oleylamine.
Perimyocarditis and myopericarditis are inflammatory conditions of the pericardium and myocardium, often of idiopathic or infectious etiology, with viral infections being the most common. Nonrheumatic streptococcal myopericarditis (NSM) is a rare condition that can mimic acute myocardial infarction. This case report presents a 22-year-old male with no prior medical history who developed NSM following a streptococcal pharyngitis infection. The patient presented with pleuritic chest pain, tightness, and decreased exercise tolerance. Laboratory studies revealed elevated troponin levels and positive Streptococcus G antigen. Treatment included ampicillin-sulbactam, colchicine, ibuprofen, and dexamethasone. The patient's symptoms resolved, and he was discharged with amoxicillin-clavulanate, colchicine, and ibuprofen.
<P>PROBLEM TO BE SOLVED: To provide a method for improving aromatic odor of food or drug medicines by which favorable aromatic odor leading to good taste of the food or the drug medicines among aromatic odors generated when heating the food or the drug medicines are effectively added to the food or the drug medicines or effectively enhanced.  <P>SOLUTION: The method for improving aromatic odor of food or drug medicine comprises utilizing aromatic components generated by aminocarbonyl reaction using D-psicose. The aromatic odor to be improved comprises an aromatic odor creating flavor peculiar to the food or the drug medicines. The method enables the aromatic odor and also a toasted color to be imparted to the food and the drug medicines. The aromatic components comprise the heated ones obtained by addition of D-psicose before heated, or generated by addition of D-psicose before heated. The aromatic components comprise the ones composed of pyrazine and/or furanone. The D-psicose is used in a form of mixture with D-fructose.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Background and Objectives: Patients with previous acute myocardial infarction are at significantly higher risk of recurrent events. Early and intensive lipid-lowering therapy targeting low-density lipoprotein cholesterol is a key strategy for reducing cardiovascular risk in post-acute myocardial infarction patients worldwide. This study aimed to assess patients' real-life lipid-lowering treatment gaps after acute myocardial infarction using a global network, TriNetX, of anonymous, real-time patient data. The uniqueness of the study was the use of the novel, evolving, and constantly improving TriNetX platform and the evaluation of its feasibility for clinical research. Materials and Methods: A retrospective study was conducted on global repository patients in 2020, diagnosed with acute myocardial infarction, with a three-year follow-up. Results: After acute myocardial infarction, the prescribing rate of lipid-lowering medication (statins, ezetimibe and PCSK9I) was insufficient to reach target LDL-C values. The mean LDL-C level decreased from 2.7 mmol/L (103 mg/dL) as measured on the day of AMI to 1.97 mmol/L (76 mg/dL) between 31D and 3M. During the second and third years, the mean LDL-C value was stable (around 2.0 mmol/L (78 mg/dL)). LDL-C goals were not sufficiently reached, as only 7-12% of patients were reported to have LDL-C values < 55 mg/dL (1.4 mmol/L) and 13-20% of patients were reported to have LDL-C values < 70 mg/dL (1.8 mmol/L) during the follow-up periods. This means that a substantial number of patients remain at a very high risk for CV complications and mortality. Most cardiovascular complications happen within three months after acute myocardial infarction. Conclusions: Gaps remain between the recommendations for managing LDL-C in guidelines and what occurs in real life. The TriNetX platform is an innovative platform with significant potential and should be further developed for clinical research, as it enables the use of valuable interinstitutional data.
BACKGROUND: Predicting time to renal replacement therapy (RRT) is important in patients at high risk for end-stage kidney disease. We developed and validated machine learning models for predicting the time to RRT and compared its accuracy with conventional prediction methods that uses the rate of estimated glomerular filtration rate (eGFR) decline.
METHODS: Data of adult chronic kidney disease (CKD) patients who underwent hemodialysis at Oita University Hospital from April 2016 to March 2021 were extracted from electronic medical records (N = 135). A new machine learning predictor was compared with the established prediction method that uses the eGFR decline rate and the accuracy of the prediction models was determined using the coefficient of determination (R2). The data were preprocessed and split into training and validation datasets. We created multiple machine learning models using the training data and evaluated their accuracy using validation data. Furthermore, we predicted the time to RRT using a conventional prediction method that uses the eGFR decline rate for patients who had measured eGFR three or more times in two years and evaluated its accuracy.
RESULTS: The least absolute shrinkage and selection operator regression model exhibited moderate accuracy with an R2 of 0.60. By contrast, the conventional prediction method was found to be extremely low with an R2 of -17.1.
CONCLUSIONS: The significance of this study is that it shows that machine learning can predict time to RRT moderately well with continuous values from data at a single time point. This approach outperforms the conventional prediction method that uses eGFR time series data and presents new avenues for CKD treatment.
The present invention relates to the management of chronic pain without requ iring administration of narcotics, and to self-managemen t of pain on an outpatient basis. The invention further relates to facilitatin g detoxification and treatment of substance addiction. A ccordingly, the present invention is broadly directed to a method for treating pain in a subject comprising administering via a nasal route a do se of ketamine effective to alleviate pain to a subject suffering from pain. Th e invention is further directed to a method for facilita ting detoxification and treating substance addiction in a subject comprising admi nistering via a nasal route a dose of ketamine effective to facilitate detoxification or treat substance addiction. In a further embodim ent, the present invention provides for pulmonary admini stration of ketamine by inhalation. Nasal administration of ketamine advantageously a llows for patient self administration of the drug, which provides for pain management or treatment of a substance addiction on an out patient basis. Moreover, ketamine administration in nasa l sprays and inhalers are generally socially acceptable. In a specific example , a patient suffering from intractable bladder pain cont rolled breakthrough pain by nasal administration of about 16 mg to about 32 mg of k etamine per dose.
Nursing staff will apply 2 grams of diclofenac 1% gel topically to the posterior cervical region of the subject four times daily for 14 days. A questionnaire consisting of a Numeric Assessment Scale (NAS) and Headache Impact Test (HIT-6) will be administered at baseline (day 1), day 7, and at the study conclusion (day 14). A complete metabolic panel will obtained on day 0 and on day 14.
1452344 Virus vaccines RECHERCHE ET INDUSTRIE THERAPEUTIQUES 7 Feb 1974 [9 Feb 1973] 05595/74 Heading A5B [Also in Division C6] A viable stable virus suspension suitable for use in vaccines comprises a cell-free preparation of a cell-associated virus and a stabilizing composition which is a buffered, at pH 6.5-7.5, aqueous solution of 0.1-10% polyvinylpyrrolidone whose average M.Wt. is up to 40000, 2-10% sucrose, 0.5-0.2% of an alkali metal or alkaline earth metal salt of glutamic acid, and 0.1-0.5% of a chelating agent for bivalent metal cations. The chelating agent may be an edetate alkali metal salt. The virus may be a group B herpes virus, e.g. turkey herpes virus, or varicellazoster virus. The method of producing the suspension may comprise mixing a suspension of infected cells with the stabilising composition before disrupting the cells. The obtained virus suspension may be further lyophilised.
Participants assigned to the Multielectrode Mapping arm will undergo VT ablation within 48 hours after baseline evaluation. The Mapping procedure will be performed with either a Pentaray or Octaray catheter (Biosense Webster; each 45 catheters, randomly allocated). Catheter ablation of potential diastolic pathways and Scar homogenisation will be performed with a irrigated 3.5mm tip catheter (QDot; Biosense Webster).
The individualized resistance exercise program is based on participants' baseline 1-repetition maximum muscular strength assessment (i.e., the maximum lifted for 1 repetition) and is aligned with current cancer-specific exercise recommendations. The resistance exercise program will follow the FITT principle (frequency, intensity, time, and type). Sessions will be 35-45 minutes in duration.
1,190,721. Treating microcapsules. NATIONAL CASH REGISTER CO. 7 Jan., 1969 [29 Jan., 1968], No. 948/69. Heading B8C. The impermeability of the hydrophilic polymeric material walls of microcapsules is improved by dispersing the capsules in a liquid in which the capsule walls swell and which includes or has added to it a first component of a condensation polymer which penetrates the interstices of the capsule walls and, optionally, complexes with the wall material. Thereafter, the second component of a condensation polymer is added which is then caused to react with the first component to form a condensation polymer in the interstices of the hydrophilic polymer wall material. Suitable first reactants are water-soluble polyhydroxy aromatics, e.g. resorcinol, catechol, phloroglucinol, hydroquinone and tannic acid (others are mentioned) and suitable second reactants are aldehydes, e.g. formaldehyde, glyoxal, furfural or glutaraldehyde, and amines. Specified hydrophilic capsule wall materials include gelatine, gum arabic, carrageenan, cationic starch, polyethylene oxide, melamine/formaldehyde resin, polyvinyl alcohol, polyvinylpyrrolidone, polyacrylic acid and maleic anhydride copolymers with ethylene, styrene and alkyl vinyl ethers.
Renal cell carcinoma (RCC) is one of the top ten cancer types in the US. One-third of RCCs are metastatic and associated with a poor 5-year survival rate of 8%. Metastatic RCC is usually treated with targeted therapy or immunotherapy which is costly (\>$10,000 per month) and has low response rate (\<30%). Effective identification of the most appropriate drugs for a patient relies on noninvasive imaging to assess early response to the drugs. However, current practice by anatomical imaging such as computed tomography (CT) or magnetic resonance imaging (MRI) can only assess the response at two months after initialing targeted therapy. This approach exposes many patients to highly toxic, high expensive treatment without any benefit for months and delays initiation of other effective therapies.

The investigators hypothesize that functional perfusion imaging by positron emission tomography (PET) can enable RCC response assessment as early as at 1-2 weeks given that RCC is highly related to angiogenesis and most targeted drugs for RCC are antiangiogenic. However, clinical options for functional renal imaging are very limited. While dynamic contrast-enhanced CT or MRI can be used for perfusion imaging, their use is restricted because 30% of RCC patients have chronic kidney diseases with renal dysfunction and are at higher risk for contrast-induced nephropathy and nephrogenic systemic fibrosis. Existing PET radiotracers (e.g., 15O-water) for perfusion imaging are short-lived and generally unavailable for clinical use. This project explores parametric PET perfusion imaging using the widely accessible 18F-fluorodeoxyglucose (FDG). 18F-FDG PET is conventionally used for metabolic imaging and has been rarely used for imaging kidneys because physiological excretion of 18F-FDG into renal pelvis contaminates image quality for renal tumor assessment. The investigators explore the potential of the metabolic radiotracer 18F-FDG for perfusion imaging by employing four-dimensional (4D: 3D space plus 1D time) dynamic scanning and tracer kinetic modeling, leading to parametric imaging of FDG perfusion kinetics without being affected by 18F-FDG excretion. The parametric PET method can potentially identify RCC response and assess drug efficacy with 1-2 weeks of treatment as compared to 2 months by current anatomical imaging methods.
BACKGROUND: Anaemia, blood loss, and blood transfusion are critical aspects of patient care in major orthopaedic surgery. We assessed hospital adherence to guideline-recommended Patient Blood Management (PBM) care, analysed variations between hospitals, and validated two composite indicators of hospital PBM performance in patients undergoing total knee arthroplasty (TKA) or total hip arthroplasty (THA).
METHODS: This retrospective cohort study included all primary TKA and THA procedures performed during 2021 across 39 hospitals in Spain. We assessed hospital adherence to key guideline-recommended PBM interventions using nine individual quality indicators and two types of composite quality indicators (cQIs): opportunity-based (cQI1) and all-or-none (cQI2). We validated these cQIs by analysing their associations with the adjusted total transfusion index using linear regression.
RESULTS: We included 8561 patient episodes from 33 hospitals in the analysis. Delivery of PBM care was similar for TKA and THA. Patients received 62% of the analysed PBM interventions and only 12% of patients underwent the full PBM pathway. Higher hospital cQIs scores were associated with a lower adjusted total transfusion index, both in TKA and THA. The greatest association was found for cQI1 in THA patients (β=-1.18 [95% confidence interval -2.00 to -0.36]; P=0.007).
CONCLUSIONS: Hospital adherence to guideline-recommended patient blood management care in total hip and knee arthroplasty was suboptimal and varied across centres. Using data that are widely available in hospitals, quality indicators and composite scores could become valuable tools for patient blood management monitoring and comparisons between healthcare organisations.
Patients receive porfimer sodium IV over 3-5 minutes. Beginning 24 hours later, patients undergo tumor resection and/or radical pleurectomy followed by intraoperative photodynamic therapy to the pleural space.